Full Text View
Tabular View
No Study Results Posted
Related Studies
LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis
This study has been completed.
Study NCT00608894   Information provided by Veloxis Pharmaceuticals

First Received on January 23, 2008.   Last Updated on October 21, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Autoimmune Hepatitis
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis, Autoimmune
More general conditions related to this trial
Autoimmune Diseases
Digestive System Diseases
Enterovirus Infections
Hepatitis, Chronic
Hepatitis, Viral, Human
Immune System Diseases
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
LCP-Tacro (tacrolimus)
Azathioprine
Additional drug interventions recognized in this trial
Prednisone
Tacrolimus
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antirheumatic Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Veloxis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services